Abstract
Over the last decade an increasing number of studies have been published reporting on the inhibitory potency or selectivity that several types of ligands show against human galectin-3 (hGal-3). The reason for this interest lies in the many important roles galectins play both in intra and extra-cellular functions. Among galectins, galectin-3 stands out because it is the only known member of its subfamily in mammals, is small and monomeric but capable of aggregating, and is known to be involved in a large number of disease processes, from cancer to heart failure. These characteristics and roles make hGal-3 an ideal target for drugs. Since it binds β-galactosides, like the rest of the galectin family of proteins, the search and design of potent and at the same time selective inhibitors for it is not an easy task. Herein we discuss the chemical features of the most potent inhibitors described so far, as well as the structural basis of their exhibited selectivity, in order to shed light on the rational design of drugs against this target.
Keywords: Lectin, galectin-3, inhibitor, selectivity, galactose-specific receptor.
Current Medicinal Chemistry
Title:Human Galectin-3 Selective and High Affinity Inhibitors. Present State and Future Perspectives
Volume: 20 Issue: 24
Author(s): R. Tellez-Sanz, L. Garcia-Fuentes and A. Vargas-Berenguel
Affiliation:
Keywords: Lectin, galectin-3, inhibitor, selectivity, galactose-specific receptor.
Abstract: Over the last decade an increasing number of studies have been published reporting on the inhibitory potency or selectivity that several types of ligands show against human galectin-3 (hGal-3). The reason for this interest lies in the many important roles galectins play both in intra and extra-cellular functions. Among galectins, galectin-3 stands out because it is the only known member of its subfamily in mammals, is small and monomeric but capable of aggregating, and is known to be involved in a large number of disease processes, from cancer to heart failure. These characteristics and roles make hGal-3 an ideal target for drugs. Since it binds β-galactosides, like the rest of the galectin family of proteins, the search and design of potent and at the same time selective inhibitors for it is not an easy task. Herein we discuss the chemical features of the most potent inhibitors described so far, as well as the structural basis of their exhibited selectivity, in order to shed light on the rational design of drugs against this target.
Export Options
About this article
Cite this article as:
Tellez-Sanz R., Garcia-Fuentes L. and Vargas-Berenguel A., Human Galectin-3 Selective and High Affinity Inhibitors. Present State and Future Perspectives, Current Medicinal Chemistry 2013; 20 (24) . https://dx.doi.org/10.2174/09298673113209990163
DOI https://dx.doi.org/10.2174/09298673113209990163 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Importance of Early Diagnosis and Treatment in Peripheral Arterial Disease: Insights from the PARTNERS and REACH Registries
Current Vascular Pharmacology Editorial [Hot Topic:Drug Targets in Ageing and Age-Associated Diseases (Executive Editors: C. Caruso and E. Jirillo)]
Current Pharmaceutical Design β-Adrenergic Over-Stimulation and Cardio-Myocyte Apoptosis: Two Receptors, One Organelle, Two Fates?
Current Drug Targets Preface [Hot Topic: Antihypertensive Drugs (Executive Editor : Gregory Y.H. Lip)].
Current Pharmaceutical Design Kringle Structures and Antiangiogenesis
Current Medicinal Chemistry - Anti-Cancer Agents Signal Transduction in Human Cutaneous Melanoma and Target Drugs
Current Cancer Drug Targets The Role of Autophagy in the Pathogenesis of Ischemic Stroke
Current Neuropharmacology Strategies to Convert PACAP from a Hypophysiotropic Neurohormone Into a Neuroprotective Drug
Current Pharmaceutical Design Hypothalamic mTOR: The Rookie Energy Sensor
Current Molecular Medicine Current and Future Pharmaceutical Therapy for Rheumatoid Arthritis
Current Pharmaceutical Design TNF-α and Ghrelin: Opposite Effects on Immune System, Metabolism and Mental Health
Protein & Peptide Letters Inhaled Insulin and the Lung
Current Medicinal Chemistry Mitochondrial Dysfunction and Lipid Homeostasis
Current Drug Metabolism Bayes Syndrome and Imaging Techniques
Current Cardiology Reviews Integrin Signaling Networks in the Pathobiology of Vascular Smooth Muscle Cells
Vascular Disease Prevention (Discontinued) Circulating miRNAs in Successful and Unsuccessful Aging. A Mini-review
Current Pharmaceutical Design Recent Progress in Therapeutic and Diagnostic Applications of Lanthanides
Mini-Reviews in Medicinal Chemistry Determinants of Perceived Severity of Hypertension and Drug-Compliance in Hypertensive Patients
Cardiovascular & Hematological Disorders-Drug Targets Neuroprotection & Mechanism of Ethanol in Stroke and Traumatic Brain Injury Therapy: New Prospects for an Ancient Drug
Current Drug Targets Oxidative Stress and Mitochondrial Dysfunction in Type 2 Diabetes
Current Pharmaceutical Design